Zuoli Pharmaceutical announced that revenue for the first half of 2026 was 1,764 billion yuan, up 10.30% year on year; net profit attributable to shareholders of listed companies was 375 million yuan, up 0.38% year on year; net profit after deducting non-recurring profit and loss was 374 million yuan, up 0.53% year on year. The company plans to pay a cash dividend of 3.5 yuan for every 10 shares without using the Provident Fund to increase share capital; the issuance of convertible corporate bonds to unspecified targets was reviewed and approved by the Shenzhen Stock Exchange Listing Review Committee on August 21, 2026.

Zuoli Pharmaceutical announced that revenue for the first half of 2026 was 1,764 billion yuan, up 10.30% year on year; net profit attributable to shareholders of listed companies was 375 million yuan, up 0.38% year on year; net profit after deducting non-recurring profit and loss was 374 million yuan, up 0.53% year on year. The company plans to pay a cash dividend of 3.5 yuan for every 10 shares without using the Provident Fund to increase share capital; the issuance of convertible corporate bonds to unspecified targets was reviewed and approved by the Shenzhen Stock Exchange Listing Review Committee on August 21, 2026.